Medarex to Start Phase III Trial Biopharmaceutical company Medarex Inc. said Monday that it reached a special protocol assessment agreement with the Food and Drug Administration to start a late-stage clinical trial for its MDX-010 drug as a combination treatment for melanoma patients.